Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-25-326263
Filing Date
2025-12-19
Accepted
2025-12-19 12:32:00
Documents
5

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 19523
2 EX-99.A ck0000000000-ex99_a.pdf EX-99.A 131007
3 EX-99.F ck0000000000-ex99_f.pdf EX-99.F 990193
4 EX-99.G ck0000000000-ex99_g.pdf EX-99.G 892171
5 EX-99.H ck0000000000-ex99_h.pdf EX-99.H 1003739
  Complete submission text file 0001193125-25-326263.txt   4177822
Mailing Address TOLDBODGADE 33 1253 COPENHAGEN K G7 00000
Business Address TOLDBODGADE 33 1253 COPENHAGEN K G7 00000
GENMAB A/S (Filed by) CIK: 0001434265 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address YALELAAN 62 3584 CM UTRECHT DE
Business Address YALELAAN 62 3584 CM UTRECHT DE 31 030 253 8800
Merus N.V. (Subject) CIK: 0001651311 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-89510 | Film No.: 251586509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)